Rhapsido Becomes First FDA-Approved Therapy for Symptomatic Dermographism
Novartis' Rhapsido (remibrutinib) became the first FDA-approved therapy for symptomatic dermographism, extending its reach beyond CSU and creating a dual-indication chronic hives franchise.